bevacizumab
ONS-5010-008
Phase 3 mab completed
Quick answer
bevacizumab for Neovascular Age-related Macular Degeneration is a Phase 3 program (mab) at Outlook Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Outlook Therapeutics
- Indication
- Neovascular Age-related Macular Degeneration
- Phase
- Phase 3
- Modality
- mab
- Status
- completed